A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Trastuzumab and Tislelizumab Versus Chemotherapy Combined with Trastuzumab with or without Pembrolizumab as First-Line Treatment for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma with HER2-high Expression.

Trial Details

NCT ID
NCT07315750
Phase
PHASE3
Sponsor
RemeGen Co., Ltd.
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Disitamab Vedotin
  • Tislelizumab
  • CAPOX (oxaliplatin/capecitabine)
  • Trastuzumab
  • Pembrolizumab
Locations (sample)
  • Beijing, BJ-Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Voluntarily consent to participate in the study and sign the informed consent form
  • Expected survival period \>12 weeks
  • ECOG Performance Status 0 or 1
  • Histologically confirmed unresectable locally advanced or metastatic --gastric/gastroesophageal junction adenocarcinoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →